<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395395</url>
  </required_header>
  <id_info>
    <org_study_id>CSMC021A2112</org_study_id>
    <nct_id>NCT00395395</nct_id>
  </id_info>
  <brief_title>Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women</brief_title>
  <official_title>A Partially-Blind, Randomized, Single-Dose, Placebo-Controlled Crossover Phase I Study Assessing the Effect of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of SMC021 0.8 mg in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a phase I study to analyze the effect of water and food intake on the bioavailability
      and pharmacodynamic of oral salmon calcitonin (SMC021) and salmon calcitonin nasal spray in
      post-menopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of oral salmon calcitonin taken in the morning with 50 ml or 200 ml water and at 10, 30 or 60 minutes before a meal</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) profile of oral salmon calcitonin taken in the morning with 50 ml or 200 ml water and at 10, 30 or 60 minutes before a meal</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of the carrier of oral salmon calcitonin, taken in the morning with 50 ml or 200 ml water and at 10, 30 or 60 minutes before a meal</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of salmon calcitonin nasal spray</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral salmon calcitonin, salmon calcitonin nasal spray</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal women

        Exclusion Criteria:

          -  Previous treatment with other osteoporosis medication

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Basel</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Basel +41 61 324 1111</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Cities</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <last_update_submitted>May 25, 2007</last_update_submitted>
  <last_update_submitted_qc>May 25, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2007</last_update_posted>
  <keyword>Postmenopausal</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>Pharmacokinetics/dynamics</keyword>
  <keyword>Calcitonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

